ID   KAT-4
AC   CVCL_6304
SY   KAT 4; KAT4
DR   BioSample; SAMN03151790
DR   cancercelllines; CVCL_6304
DR   ChEMBL-Cells; CHEMBL3307845
DR   ChEMBL-Targets; CHEMBL614008
DR   Cosmic; 886548
DR   Cosmic; 891253
DR   Cosmic; 1068626
DR   Cosmic; 1162839
DR   Cosmic; 2050372
DR   IARC_TP53; 21624
DR   PubChem_Cell_line; CVCL_6304
DR   Wikidata; Q54899532
RX   PubMed=12481943;
RX   PubMed=14522906;
RX   PubMed=17465858;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00222.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=17465858; PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11 (PubMed=17465858; PubMed=18713817)
ST   D13S317: 11,13 (PubMed=21868764)
ST   D16S539: 9,11,12
ST   D18S51: 13
ST   D21S11: 30
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 8,10,12 (PubMed=21868764)
ST   D7S820: 10 (PubMed=17465858; PubMed=18713817)
ST   D8S1179: 10 (PubMed=17465858)
ST   D8S1179: 10,16 (PubMed=18713817)
ST   FGA: 20,22
ST   TH01: 6,7
ST   TPOX: 8,9,11
ST   vWA: 16,17,18,19 (PubMed=21868764)
ST   vWA: 17,19 (PubMed=17465858; PubMed=18713817)
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
RX   PubMed=12481943; DOI=10.1089/105072502760339343;
RA   Husmark J., Heldin N.-E., Nilsson M.;
RT   "Follicular growth of a thyroid carcinoma cell line (KAT-4) with
RT   abnormal E-cadherin and impaired epithelial barrier.";
RL   Thyroid 12:781-790(2002).
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E.,
RA   Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.;
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G.,
RA   Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.;
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).